Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04777331 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

A Phase 2 study of Parkinson's Disease, sponsored by Hoffmann-La Roche.

Active
Registry status
Phase 2
Development phase
586
Enrollment target
20
Study locations

NCT04777331 is a Phase 2 study of Parkinson's Disease that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 586 participants, roughly in line with the 639-participant average among 156 other Parkinson's Disease trials with a reported enrollment target. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04777331, a Phase 2 study of Parkinson's Disease, is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
586 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

Conditions Studied

Parkinson's Disease

Interventions

  • DRUG Placebo
  • DRUG Prasinezumab

Study Locations (20)

California

  • Neurology Center of North Orange County - Fullerton
  • UC San Diego - La Jolla
  • Keck School of Medicine of USC - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles
  • University of California San Francisco - San Francisco

Florida

  • JEM Research LLC - Atlantis
  • Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
  • Renstar Medical Research - Ocala
  • University of South Florida - Tampa
  • Charter Research - Winter Park/Orlando - Winter Park

Illinois

  • Northwestern University Feinberg School Of Medicine - Chicago
  • Southern Illinois University, School of Medicine - Springfield

Michigan

  • Quest Research Institute - Farmington Hills
  • Henry Ford Hospital - West Bloomfield

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Barrow Neurological Institute - Phoenix

Colorado

  • CenExel Rocky Mountain Clinical Research, LLC - Englewood

Connecticut

  • Institute for Neurodegenerative Disorders - New Haven

Trial Details

FieldValue
Enrollment Target 586 participants
Start Date 2021-05-05
Est. Completion 2026-12-30
Phase Phase 2

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04777331

The ClinicalTrials.gov registry entry for NCT04777331 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 586 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 639-participant average among 156 other Parkinson's Disease trials with a reported enrollment target. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04777331 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT04777331 about?

NCT04777331 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease". This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

What is the current status of trial NCT04777331?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 586 participants. The study started on 2021-05-05. Estimated completion is 2026-12-30.

What conditions does trial NCT04777331 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT04777331?

The interventions under investigation include: Placebo (DRUG), Prasinezumab (DRUG).

Who is sponsoring clinical trial NCT04777331?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04777331 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.